Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
From Iowa to Brazil, researchers are discovering there is a distinct association between complaints, worries and random rants on the social media site and the spread of medical issues as wide-ranging as the flu, dengue fever and pollen-induced allergies.
Winner Medical Group Inc., a leading manufacturer of medical dressings, medical disposables and non-woven fabric made from 100% natural PurCotton products in China, today reported consolidated financial results for the third quarter ended June 30, 2011.
Each year, 200,000 Americans are hospitalized due to flu-related complications.
That number can rise or fall - often dramatically - based on the effectiveness of the selected flu vaccine, said Dr. Jorge Parada, director of infection prevention and control at Loyola University Health System.
NanoViricides, Inc. recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide™, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.
Researchers have finally found the first antibody which can fight all types of the influenza A virus. The results of the experiments on flu-infected mice, published in Science Express, showed the antibody could be used as an “emergency treatment” for flu as well.
Social media tools like Facebook, Twitter and Foursquare may be an important key to improving the public health system's ability to prepare for, respond to, and recover from disasters, according to a New England Journal of Medicine "Perspective" article from the Perelman School of Medicine at the University of Pennsylvania to be published this week.
Aetna today announced second-quarter 2011 operating earnings of $522.8 million, or $1.35 per share, a per share increase of 29 percent over 2010.
Researchers from Australia determined that pediatric liver transplant patients who received a single-dose of the H1N1 vaccine were not adequately protected against the virus compared to healthy children.
NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.
A final review result from Europe's drug regulatory agency released a positive link between narcolepsy and the Pandemrix 2009 H1N1 vaccine. The agency recommends a labeling change that limits the vaccine's use in children and teens to when protection is needed and seasonal trivalent vaccine isn't available.
Australia is gripped with a fourfold increase in the number of people suffering flu. This rise is even before the usual peak season in August and September. Already nearly 8,000 cases have been reported compared with about 2,000 at the same time last year. The increase has disproportionately affected Queensland, NSW and South Australia. In January and February more than 1,700 people were recorded with flu, compared with fewer than 300 the year before.
CEL-SCI Corporation announced today that it has expanded the licensing agreement with Teva Pharmaceutical Industries Ltd. for its cancer drug Multikine.
The U.S. Food and Drug Administration announced today that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the six manufacturers licensed to produce and distribute influenza vaccine for the United States.
According to an announcement from the Food and Drug Administration (FDA) on Monday, it has approved the new flu vaccine for the season beginning this year. Each year the FDA works with other federal agencies and global health experts to design a vaccine to protect against the three viral strains most likely to cause the flu.
The Influenza Specialist Group (ISG) is today warning that high rates of influenza outbreaks have been confirmed in QLD, SA and NSW, but there is still time for most Australians, especially those in at-risk groups, to protect themselves and those around them.
MedImmune has received confirmation from the U.S. Food & Drug Administration (FDA) that the Agency has filed the Company's supplemental Biologics License Application (sBLA) for a quadrivalent (four-strain) version of FluMist® (Influenza Vaccine Live, Intranasal). The company submitted the sBLA early in the second quarter of this year.
A test, novel breath measuring the immune response to the H1N1 flu virus, could help to ease future vaccine shortages by identifying the people who have already been infected with the flu virus.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated in its Phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.
A new University of Maryland-led study finds that 'sex' between the virus responsible for the 2009 flu pandemic (H1N1) and a common type of avian flu virus (H9N2) can produce offspring -- new combined flu viruses -- with the potential for creating a new influenza pandemic.
In a large five nation study from Europe it was seen that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barré Syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.